ArticleProbiotics and antimicrobial proteins2026
Rational Design and In Silico Evaluation of a Dual-Action Antimicrobial Peptide Targeting Efflux Pump and Membrane Integrity in Pseudomonas aeruginosa.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The increasing prevalence of multidrug-resistant (MDR) Pseudomonas aeruginosa, largely associated with overexpression of the MexAB-OprM efflux pump, highlights the need for alternative antimicrobial strategies. In this study, antimicrobial peptide (AMP) candidates were rationally designed using the Artificial Neural Network (ANN) and Random Forest (RF) models implemented in the CAMPR4 platform. Approximately 18,000 AMP sequences were screened, resulting in nine candidate peptides that were subsequently evaluated for physicochemical properties, predicted hemolytic activity, and antimicrobial potential using the dbAMP framework. Five non-hemolytic peptides (1ANN, 2ANN, 4RF, 5RF, and 6RF) were selected for further analysis based on their predicted physicochemical characteristics and antimicrobial profiles. Molecular docking against the three components of the MexAB-OprM efflux pump (MexA, MexB, and OprM) predicted binding affinities ranging from - 7.1 to - 14.1 kcal mol⁻¹. Among the evaluated peptides, 2ANN was the only peptide predicted to form a hydrogen bond between Lys15 and Asp61 of MexA. Molecular dynamics simulations demonstrated that the 2ANN-MexA complex remained structurally stable over 200 ns, while membrane simulations showed spontaneous adsorption of 2ANN onto a Gram-negative membrane and persistent membrane association throughout the simulation. Collectively, these computational analyses identified 2ANN as a promising AMP candidate for further investigation against MDR P. aeruginosa. However, as the findings are based exclusively on computational prediction and simulation, experimental validation, including peptide synthesis, antimicrobial susceptibility testing, hemolytic assays, and efflux pump inhibition studies, is required to confirm its biological activity and mechanism of action.
Indexed as
Identifiers
42709334What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.